AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01920932 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.
Study NCT02020395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: test meal (500 kcal)
Description: whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
Study NCT02020395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: test meal (500 kcal)
Description: whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
Study NCT02389088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: In Phase II, letrozole, 5 mg/day, will be given for 14 days
Study NCT03472027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-145
Description: Anti-CTLA-4 monoclonal antibody, IV infusion
Study NCT02939235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crushed ticagrelor followed by morphine
Description: Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
Study NCT02939235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crushed ticagrelor, morphine,metoclopramide
Description: Crushed ticagrelor (180 mg) orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
Study NCT03494309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction & Internal Fixation
Description: Patients underwent surgery and the fractures were reduced under direct vision followed by internal fixation with titanium plates and screws
Study NCT03494309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Reduction & External Fixation
Description: Patients underwent closed reduction of the fracture and external fixation by arch bars \& guided elastics
Study NCT01075204 — intervention group
Intervention type: DRUG
Intervention: clarithromycin modified release 500 mg
Description: clarithromycin modified release 500 mg for 7 days
Study NCT04951245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UC group: ultrasound-assisted CNSs guided
Description: 1ml of CNSs was subcutaneously injected into the areolar area in the upper outer quadrant of the breast. The injection site was massaged for 15 minutes to promote drainage of the tracer to the axilla. During the intraoperative ultrasound-assisted procedure, an ultrasound diagnostic system was used. Before the incision, ultrasound-guided exploration of SLNs was performed by placing the probe on the lateral border of the breast and sliding cranially along the lateral border of the pectoralis major muscle . A sterile skin marker was then used to mark the optimal site of incision over the targeted lymph nodes, and the distance from the skin to the nodes was measured by ultrasound and recorded in millimeters. Blunt dissection was carried out to identify the CNSs-stained nodes around the marked region. Ultrasonography probe was placed repeatedly in or around the wound at different angles for adequate visualization if SLNs could not be localized with further dissection.
Study NCT04951245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GC group: CNSs plus ICG dual-tracer-guided
Description: The preparation of CNSs mapping was identical to that of the UC group. 1ml of diluted ICG was subsequently injected into the areolar area in the upper outer quadrant of the breast. A NIR camera was used to visualize the subcutaneous lymph vessels and localized the SLNs. All fluorescent or black-stained lymph nodes along with any palpable suspicious nodes were removed. The remaining surgical field was reexamined to ensure complete resection of fluorescent lymph nodes.
Study NCT00945139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1
Study NCT00945139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression
Study NCT03780868 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external dacryocystorhinostomy
Description: external DCR under general anesthesia with standard sterilization procedures.
Study NCT03780868 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: canalicular silicone intubation with MMC
Description: canalicular silicone intubation with MMC under general anesthesia with standard sterilization procedures.
Study NCT02569216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Inhibition (EI)
Description: constant direct current 1-20mA transvaginal 10 second bursts only when needed
Study NCT01619345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.
Study NCT01974375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing \<40 kg)
Study NCT01974375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole 100\~200mg/day, IV care until oral medication becomes possible
Study NCT03417817 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bravo
Description: wireless pH monitoring over 96 hours
Study NCT01164332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NRL972
Description: Two-hour intravenous infusion of 5 and 15 mg per hour
Study NCT01863251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Study NCT05750719 — intervention group
Intervention type: GENETIC
Intervention: BRCA1/2 genetic testing
Description: All patients will undergo genetic testing for BRCA 1 and BRCA 2 germline mutations, employing next generation sequencing (NGS) techniques.
Study NCT04072133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditative Movement
Description: Intervention will be taught by a certified Tai Chi Easy (TCE) group practice leader. The TCE movements will be repeated in differing sequences and time-frames during the course of the study. The variety and combination of the exercises will begin easy and progress to more advanced movements and/or intensities as the study progresses and participants become more experienced and comfortable with the routine. Participants spend one hour in class each week for a total of eight weeks.
Study NCT01372475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hymovis Intra-articular Injection
Description: Hymovis Intra-articular injection
Study NCT01372475 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline Injection
Description: Placebo Intra-articular injection
Study NCT03349944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The duration of the training intervention is 10 weeks of either moderate exercise og high intensity interval training.
Study NCT03349944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: The duration of the training intervention is 10 weeks of either moderate exercise og high intensity interval training.
Study NCT01863251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Study NCT00906724 — intervention group
Intervention type: PROCEDURE
Intervention: Aerobic exercise
Description: A graded exercise stress test (GXT) will be done under cardiologist supervision.~Subjects will undergo three month of supervised aerobic exercise.
Study NCT02602860 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]UCB-J
Description: * Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 20 mCi~* Route of Administration: iv
Study NCT02602860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 10 mg/ml~* Route of Administration: iv
Study NCT02602860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: * Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 100 mg/ml~* Route of Administration: iv
Study NCT02602860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Tablets for oral intake~* Concentration: 25 mg~* Route of Administration: oral
Study NCT02068443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT02068443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT02068443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin hydrochloride
Description: Metformin hydrochloride tablets
Study NCT02068443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: Metformin hydrochloride tablets
Study NCT02068443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin hydrochloride Placebo
Description: Metformin hydrochloride placebo-matching tablets
Study NCT02068443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride Placebo
Description: Metformin hydrochloride placebo-matching tablets
Study NCT03649685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous theta burst stimulation (cTBS)
Description: 50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
Study NCT03649685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Description: 50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
Study NCT01551277 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-BREATH STACKING
Description: The control group used the same circuit in the intervention group, but without occlusion of the expiratory branch and followed the same protocol to capture the images, ie, basal respiration for five minutes, then three periods of breathing through the mask, the equivalent time the period of technical BS, and five minutes of respiration. The volunteers were instructed to maintain respiration during the period they were using the mask.
Study NCT01551277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BREATH STACKING
Description: In the intervention group used a silicon mask, involving the nose and mouth with two outputs, one containing the Wright spirometer MARK 8 analog output and the other was occluded. It was explained that the mask would only allow the air entering during inspiration, and that should inspire the volunteer gradually filling the lungs with air until you feel that completely filled with an average time of 20 seconds, as shown in figure 1 obtained during the method of BS. The end of the technique would be in two situations: when the volunteer asked for it through a hand gesture, or when prearranged by Wright spirometer, was observed by the researcher that there was no change in the inspired volume.
Study NCT00413829 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal ranibizumab with photodynamic therapy
Description: Intravitreal injection, photodynamic therapy
Study NCT02849782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fampridine
Description: Oral intake of 10 mg twice daily
Study NCT02849782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine
Description: Oral intake of 10 mg twice daily
Study NCT03649685 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: shame rTMS
Description: The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
Study NCT01758783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: amino acid：1.2-2g/(kg·d) Glutamine：0.5g /(kg·d)
Study NCT04299919 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally invasive treatment
Description: All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
Study NCT04299919 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: All hepatocellular carcinoma (HCC) patients received hepatectomy.
Study NCT01758783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glutamine
Description: amino acid：1.2-2g/(kg·d) Glutamine：0.5g /(kg·d)
Study NCT02900638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring
Description: Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on the development of a social bond between mentor and mentee.
Study NCT03405935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food.
Study NCT02941965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICSI without PGS
Description: Selection of embryos are based on morphology criteria on the 5th day of ICSI.
Study NCT02941965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICSI with PGS
Description: PGS will be applied to selected embryos on the 5th day of ICSI.
Study NCT05100524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: The motivational interviewing technique is a client-focused, directive form of counseling to create behavior change. Its main goal is to discover and solve ambivalence. This method is especially useful for people who are reluctant or ambivalent to change.
Study NCT05100524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ongoing treatment
Description: Patients with total knee replacement receive standard nurse care. Treatment is applied. He does his own exercises at home.
Study NCT01717404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexiletine
Description: 6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
Study NCT02243800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cholecalciferol versus placebo
Study NCT02243800 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol versus placebo
Study NCT04202991 — intervention group
Intervention type: OTHER
Intervention: Exposure - pain
Description: Groups are defined by their naturally occurring exposure to pain or not
Study NCT00249444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine
Study NCT00314028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control standard of care treatment
Description: Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
Study NCT00314028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control standard of care treatment
Description: Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
Study NCT02946268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Change in administration of ropivacaine. Rate, Volume and Interval of bolus altered.
Study NCT00249444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01499667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod 0.5 mg capsules for oral administration once daily
Study NCT01499667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules for oral administration once daily.
Study NCT02673489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV
Study NCT02673489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Study NCT02673489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Study NCT01918904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
Study NCT01918904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
Study NCT04941235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound and nerve stimulator
Description: nerve stimulator and ultrasound guided interscalene brachial plexus block
Study NCT02747706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-to-parent mentoring
Description: phone, SMS/text, and smartphone-based support
Study NCT01715350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM012
Description: * The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks
Study NCT01715350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks
Study NCT01715350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks
Study NCT00403780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.~Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
Study NCT00403780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
Study NCT03283969 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Freeze Dried Strawberry Powder
Description: Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
Study NCT03283969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze Dried Strawberry Powder
Description: Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
Study NCT03283969 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric powder
Description: Isocaloric powder
Study NCT03283969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isocaloric powder
Description: Isocaloric powder
Study NCT01332838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compression stockings
Description: standard 30to 40 mm Hg thigh high compression stockings
Study NCT01332838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compression stockings (Sigvaris )
Description: Specialized monoleg compression
Study NCT02775942 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMOVAC-POLIO
Description: IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
Study NCT02775942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPOVAC 1.5:5:5
Description: IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
Study NCT02775942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPOVAC, 3:10:10
Description: IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
Study NCT02775942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPOVAC, 6:20:20
Description: IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
Study NCT01357876 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metformin
Description: withdrawral
Study NCT03895177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: contrast enhanced computed tomography
Description: pancreatic protocol CT with 80kVp tube voltage and more than 500mA tube current acquire late arterial phase and portal venous phase using volus tracking method
Study NCT00731965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella vaccination
Description: Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once